AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15300317 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically recognized cases
Number of subjects: 117
Study 15300317 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with higher depression scores
Number of subjects: 117
Study 12161101 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF 5 mcg/kg/d for 4 days, IV
Number of subjects: 60
Study 12161101 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG-CSF 10 mcg/kg/d for 4 days, IV
Number of subjects: 60
Study 12161101 — intervention group
Group type: COMPARATOR
Intervention: Normal saline for 4 days, IV (placebo)
Number of subjects: 60
Study 9527776 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐HTIG plus Td vaccine
Number of subjects: 48
Study 9527776 — intervention group
Group type: COMPARATOR
Intervention: P‐HTIG plus placebo
Number of subjects: 48
Study 7637157 — intervention group
Group type: COMPARATOR
Intervention: Oral triazolam (0.25 mg)
Number of subjects: 63
Study 7637157 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tizanidine (3 mg)
Number of subjects: 63
Study 7637157 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine (0.15 mg)
Number of subjects: 63
Study 7637157 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine-tetracaine-phenylephrine group
Number of subjects: 63
Study 2797970 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive routines
Number of subjects: 36
Study 2797970 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated extinction
Number of subjects: 36
Study 2797970 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 230893 — intervention group
Group type: COMPARATOR
Intervention: BCNU alone
Number of subjects: 21
Study 230893 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU and VM-26
Number of subjects: 21
Study 30977278 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting Balloon (CB)
Number of subjects: 41
Study 30977278 — intervention group
Group type: COMPARATOR
Intervention: Conventional Balloon
Number of subjects: 41
Study 27633135 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ) consumption, 200 ml daily for six weeks
Number of subjects: 60
Study 27633135 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 25875324 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment group receiving business training, $150, and supervision and advising.
Number of subjects: 1800
Study 25875324 — intervention group
Group type: COMPARATOR
Intervention: Participants assigned to include household partners in the program.
Number of subjects: 1800
Study 24422342 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary rewards group (chance to draw for a cash prize of $30.00 if CRT performances were at the 50th percentile or better)
Number of subjects: 20
Study 24422342 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 24422342 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (monetary rewards and control)
Number of subjects: 20
Study 21052690 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspase-1 5352 A allele carriers
Number of subjects: 104
Study 21052690 — intervention group
Group type: COMPARATOR
Intervention: Other six polymorphisms related to inflammation
Number of subjects: 104
Study 19436135 — intervention group
Group type: EXPERIMENTAL
Intervention: Light resistance exercise (15 min dumbbell exercise using 300 g brown‐rice‐filled fabric dumbbells)
Number of subjects: 7
Study 19436135 — intervention group
Group type: COMPARATOR
Intervention: Control group (resting position)
Number of subjects: 7
Study 16721686 — intervention group
Group type: EXPERIMENTAL
Intervention: Continual jejunal interposition (Group A)
Number of subjects: 34
Study 16721686 — intervention group
Group type: COMPARATOR
Intervention: Billroth II procedure (Group B)
Number of subjects: 34
Study 15187817 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemia (up to 69 mg/dl)
Number of subjects: 14670
Study 15187817 — intervention group
Group type: COMPARATOR
Intervention: Euglycaemic (80-109 mg/dl)
Number of subjects: 14670
Study 15187817 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic (>140 mg/dl)
Number of subjects: 14670
Study 15187817 — intervention group
Group type: EXPERIMENTAL
Intervention: Low normal (70-79 mg/dl)
Number of subjects: 14670
Study 15187817 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline diabetics (126-139 mg/dl)
Number of subjects: 14670
Study 15187817 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (110-125 mg/dl)
Number of subjects: 14670
Study 11209624 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 42
Study 11209624 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial ablation
Number of subjects: 42
Study 11209624 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management
Number of subjects: 42
Study 11209624 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective treatment cohort design with randomization
Number of subjects: 42
Study 9440631 — intervention group
Group type: EXPERIMENTAL
Intervention: One-week course of triple therapy with bismuth subcitrate, metronidazole, and tetracycline plus ranitidine
Number of subjects: 250
Study 9440631 — intervention group
Group type: COMPARATOR
Intervention: Six-week course of ranitidine 300 mg/day
Number of subjects: 250
Study 8517902 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (0.25 U/ml)
Number of subjects: 15
Study 8517902 — intervention group
Group type: COMPARATOR
Intervention: Control (no heparin)
Number of subjects: 15
Study 3683021 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaprozin 600 mg
Number of subjects: 8
Study 3683021 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaprozin 1200 mg
Number of subjects: 8
Study 3683021 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 50 mg
Number of subjects: 8
Study 3683021 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid 1000 mg
Number of subjects: 8
Study 29043548 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy (LSG)
Number of subjects: 70
Study 29043548 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Gastric Plication (LGP)
Number of subjects: 70
Study 27344212 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E‐coated dialyzers
Number of subjects: 32
Study 27344212 — intervention group
Group type: COMPARATOR
Intervention: Heparin‐coated dialyzers
Number of subjects: 32
Study 24636627 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific quality of life (QoL) measured by the Audit of Diabetes Dependent Quality of Life (ADDQoL19)
Number of subjects: 1876
Study 24636627 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status measured by SF-36
Number of subjects: 1876
Study 22517782 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-based bilateral arm training (TBAT)
Number of subjects: 42
Study 22517782 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted bilateral arm training (RBAT)
Number of subjects: 42
Study 22517782 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (CT)
Number of subjects: 42
Study 20738840 — intervention group
Group type: EXPERIMENTAL
Intervention: SRK II
Number of subjects: 24
Study 20738840 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric IOL Calculator
Number of subjects: 24
Study 18930629 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain Doppler echocardiography
Number of subjects: 33
Study 18930629 — intervention group
Group type: COMPARATOR
Intervention: Coronary flow velocity pattern
Number of subjects: 33
Study 16214487 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-dimensional model of the lower extremities after total hip arthroplasty
Number of subjects: 0
Study 16214487 — intervention group
Group type: EXPERIMENTAL
Intervention: Open MRI for validation of measurement error
Number of subjects: 0
Study 12423180 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sets of weight training (S-3)
Number of subjects: 16
Study 12423180 — intervention group
Group type: COMPARATOR
Intervention: 1 set of weight training (S-1)
Number of subjects: 16
Study 10423939 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole, 200 mg twice daily
Number of subjects: 52
Study 10423939 — intervention group
Group type: COMPARATOR
Intervention: Standard palliative care (toenail trimming, cleaning, and soaking)
Number of subjects: 52
Study 10423939 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 52
Study 7572630 — intervention group
Group type: COMPARATOR
Intervention: Intravenous heparin alone (Control group, n = 35)
Number of subjects: 96
Study 7572630 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intravenous nitroglycerin and heparin (n = 31)
Number of subjects: 96
Study 7572630 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intravenous isosorbide dinitrate and heparin (n = 30)
Number of subjects: 96
Study 2285626 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC-8212
Number of subjects: 83
Study 2285626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 6119025 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group receiving outpatient clinic treatment for high GGT levels
Number of subjects: 252
Study 6119025 — intervention group
Group type: COMPARATOR
Intervention: Control group (random one-half of individuals with high GGT levels)
Number of subjects: 252
Study 31442395 — intervention group
Group type: EXPERIMENTAL
Intervention: MB ultra-slim endoscope
Number of subjects: 92
Study 31442395 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultra-slim endoscope
Number of subjects: 92
Study 31562049 — intervention group
Group type: EXPERIMENTAL
Intervention: Mold-fermented cheese (MFC) 33.4 g daily for 3 months
Number of subjects: 71
Study 31562049 — intervention group
Group type: COMPARATOR
Intervention: Non-MFC (processed cheese made from mozzarella cheese and cream cheese) 33.4 g daily for 3 months
Number of subjects: 71
Study 28961832 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Nimotuzumab (gem + nimo)
Number of subjects: 192
Study 28961832 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus Placebo (gem + placebo)
Number of subjects: 192
Study 26167086 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin (10 mg/d) monotherapy
Number of subjects: 20
Study 24506429 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 37
Study 24506429 — intervention group
Group type: COMPARATOR
Intervention: Protease Inhibitor (PI) or Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Number of subjects: 37
Study 21980934 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-rush grass pollen immunotherapy with sublingual drops (Staloral)®
Number of subjects: 209
Study 21980934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 19095776 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 23371
Study 19095776 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to tumor progression (TTP)
Number of subjects: 23371
Study 19095776 — intervention group
Group type: EXPERIMENTAL
Intervention: Response rate (RR)
Number of subjects: 23371
Study 19095776 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 23371
Study 19095776 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to treatment failure
Number of subjects: 23371
Study 19095776 — intervention group
Group type: COMPARATOR
Intervention: Comparison of trials using PFS, TTP, or time to treatment failure vs. RR
Number of subjects: 23371
Study 16893378 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg d(‐1))
Number of subjects: 8
Study 16893378 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (20 mg d(‐1))
Number of subjects: 8
Study 14728265 — intervention group
Group type: EXPERIMENTAL
Intervention: Unscheduled, nighttime videoconferencing
Number of subjects: 0
Study 10385063 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5 mg twice per day)
Number of subjects: 76
Study 10385063 — intervention group
Group type: COMPARATOR
Intervention: Control (no calcitriol)
Number of subjects: 76
Study 8727432 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoInit ventilator settings
Number of subjects: 30
Study 8727432 — intervention group
Group type: COMPARATOR
Intervention: Control ventilator settings
Number of subjects: 30
Study 1838978 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (250 mg twice daily for 10 days)
Number of subjects: 95
Study 1838978 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V (250 mg four times a day for 10 days)
Number of subjects: 95
Study 6406440 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 183
Study 6406440 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 183
Study 31271705 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 1046
Study 31271705 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin
Number of subjects: 1046
Study 30393209 — intervention group
Group type: EXPERIMENTAL
Intervention: CartiNovex plus tablet
Number of subjects: 200
Study 30393209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 26945383 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyromental distance-based group
Number of subjects: 80
Study 24929834 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST)
Number of subjects: 34
Study 21933229 — intervention group
Group type: EXPERIMENTAL
Intervention: PM103 (0.1, 1.0, 10, 30, 100 or 300 mg)
Number of subjects: 144
Study 21933229 — intervention group
Group type: EXPERIMENTAL
Intervention: PM103
Number of subjects: 144
Study 20668354 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan plus amiodarone (irbesartan 150 mg/d, n=43)
Number of subjects: 85
Study 20668354 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone (n=42)
Number of subjects: 85
Study 20668354 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan plus amiodarone
Number of subjects: 85
Study 20668354 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 85
Study 17111172 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupentixol (FLX) 5.7 +/- 1.4 mg/day
Number of subjects: 35
Study 17111172 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (HAL) 8.5 +/- 5.5 mg/day
Number of subjects: 35
Study 17111172 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (RIS) 3.6 +/- 1.3 mg/day
Number of subjects: 35
Study 15983331 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher alanine aminotransferase and GGT values
Number of subjects: 1441
Study 15983331 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline phosphatase
Number of subjects: 1441
Study 15983331 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartate aminotransferase
Number of subjects: 1441
Study 15983331 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised GGT
Number of subjects: 1441
Study 12144580 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole 20 mg
Number of subjects: 24
Study 12144580 — intervention group
Group type: COMPARATOR
Intervention: esomeprazole 20 mg
Number of subjects: 24
Study 9857976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 102
Study 9857976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine plus Pindolol
Number of subjects: 102
Study 9857976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 8535670 — intervention group
Group type: EXPERIMENTAL
Intervention: Refluxing anastomosis
Number of subjects: 37
Study 8535670 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-reflux anastomosis
Number of subjects: 37
Study 8535670 — intervention group
Group type: EXPERIMENTAL
Intervention: Continent diversion
Number of subjects: 37
Study 2212087 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.2% Triclosan and 0.5% zinc citrate
Number of subjects: 0
Study 2212087 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 0
Study 75638 — intervention group
Group type: EXPERIMENTAL
Intervention: Kvadricult system
Number of subjects: 0
Study 75638 — intervention group
Group type: COMPARATOR
Intervention: Standard laboratory gonococcal culture methods
Number of subjects: 0
Study 75638 — intervention group
Group type: COMPARATOR
Intervention: Transport for 2 days
Number of subjects: 0
Study 75638 — intervention group
Group type: EXPERIMENTAL
Intervention: Transport for less than 24 hours or 'bedside' inoculation
Number of subjects: 0
Study 31539622 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 1.0mg
Number of subjects: 577
Study 31539622 — intervention group
Group type: COMPARATOR
Intervention: liraglutide 1.2mg
Number of subjects: 577
Study 31307906 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HPV self-sampling intervention
Number of subjects: 1083
Study 31307906 — intervention group
Group type: COMPARATOR
Intervention: Control group (HPV kit non-returners)
Number of subjects: 1083
Study 28239995 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSIST-linked brief intervention (BI)
Number of subjects: 806
Study 28239995 — intervention group
Group type: COMPARATOR
Intervention: Informational pamphlet on risk associated with substance use
Number of subjects: 806
Study 26106207 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV + vibrating mesh nebulizer
Number of subjects: 10
Study 26106207 — intervention group
Group type: COMPARATOR
Intervention: NIV + jet nebulizer
Number of subjects: 10
Study 23582153 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanically evoked itch stimulation on the face
Number of subjects: 0
Study 23582153 — intervention group
Group type: COMPARATOR
Intervention: Mechanically evoked itch stimulation on the arm
Number of subjects: 0
Study 23582153 — intervention group
Group type: COMPARATOR
Intervention: Histamine H1-receptor antagonists
Number of subjects: 0
Study 23582153 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of stimulation at 90 seconds
Number of subjects: 0
Study 23582153 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch-alloknesis in adjacent skin area
Number of subjects: 0
Study 21790761 — intervention group
Group type: EXPERIMENTAL
Intervention: Pastured regime
Number of subjects: 16
Study 21790761 — intervention group
Group type: COMPARATOR
Intervention: Stabled regime
Number of subjects: 16
Study 19846743 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen replacement therapy (ART) with 1.5 mg methyl testosterone for 1 year
Number of subjects: 14
Study 19846743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 17043732 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate 885 mg/day for 2 weeks (Group III)
Number of subjects: 267
Study 17043732 — intervention group
Group type: COMPARATOR
Intervention: Radioiodine therapy (all groups)
Number of subjects: 267
Study 17043732 — intervention group
Group type: COMPARATOR
Intervention: Radioiodine therapy (Group II)
Number of subjects: 267
Study 14560493 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10‐20 mg)
Number of subjects: 95
Study 14560493 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine (8‐40 mg)
Number of subjects: 95
Study 14560493 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 95
Study 14560493 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine
Number of subjects: 95
Study 11099366 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.9% CHO‐electrolyte solution (CE)
Number of subjects: 9
Study 11099366 — intervention group
Group type: COMPARATOR
Intervention: CHO‐ and electrolyte‐free sweetened placebo (PL)
Number of subjects: 9
Study 8981119 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. pFSH alone (group pFSH)
Number of subjects: 440
Study 8981119 — intervention group
Group type: COMPARATOR
Intervention: i.m. pFSH and i.m. HMG (group HMG-1)
Number of subjects: 440
Study 8981119 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. FSH-HP alone (group FSH-HP)
Number of subjects: 440
Study 8981119 — intervention group
Group type: COMPARATOR
Intervention: s.c. FSH-HP and i.m. HMG (group HMG-2)
Number of subjects: 440
Study 1585842 — intervention group
Group type: EXPERIMENTAL
Intervention: RESTRICTED DIET (800 kcal/day)
Number of subjects: 5
Study 1585842 — intervention group
Group type: COMPARATOR
Intervention: NORMAL DIET (3,000 kcal/day)
Number of subjects: 5
Study 6363398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial electrotherapy stimulation (CES)
Number of subjects: 60
Study 6363398 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 60
Study 31247643 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute cold stress
Number of subjects: 192
Study 31247643 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic cold stress
Number of subjects: 192
Study 31247643 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 192
Study 29618599 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/d (ATV10)
Number of subjects: 10001
Study 29618599 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 80 mg/d (ATV80)
Number of subjects: 10001
Study 29618599 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (both doses)
Number of subjects: 10001
Study 27507151 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rating items without qualifiers
Number of subjects: 659
Study 27507151 — intervention group
Group type: COMPARATOR
Intervention: Self-rating items with qualifiers
Number of subjects: 659
Study 27507151 — intervention group
Group type: COMPARATOR
Intervention: Self-rating items related to anatomy with qualifiers
Number of subjects: 659
Study 24486636 — intervention group
Group type: EXPERIMENTAL
Intervention: Group phone-based counseling
Number of subjects: 210
Study 24486636 — intervention group
Group type: COMPARATOR
Intervention: Mail-based newsletter
Number of subjects: 210
Study 22676819 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (gallium aluminum arsenide) at 808 nm, 1 W
Number of subjects: 20
Study 22676819 — intervention group
Group type: COMPARATOR
Intervention: Er:YAG laser at 2,940 nm, 1 W
Number of subjects: 20
Study 20206052 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block (FNB)
Number of subjects: 13
Study 20206052 — intervention group
Group type: COMPARATOR
Intervention: Control groups with multimodal pain regimens
Number of subjects: 13